The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The agreement could rise to $900 million if key commercial milestones are met
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
Subscribe To Our Newsletter & Stay Updated
